ImmunoPrecise, LiteVax begin preclinical studies of SARS-CoV-2 vaccine

By The Science Advisory Board staff writers

September 25, 2020 -- ImmunoPrecise and LiteVax have commenced preclinical SARS-CoV-2 vaccine trials.

The vaccine design is based on large datasets obtained during the analysis of ImmunoPrecise Antibodies' (IPA) SARS-CoV-2 therapeutic programs, which the firm has used to craft its spike protein variant vaccine candidates.

The candidates are combined with a novel class of synthetic carbohydrate derivatives with the final formulations aimed at high efficacy and low adverse effects, the firms said.

The preclinical study is ongoing at the Institute of Agrifood Research and Technology (IRTA) in Catalonia, Spain, and is focusing on a single, low-dose administration. In tandem, IPA and LiteVax are starting ex vivo assays, with study results expected by November 2020. From there, the companies will be able to prioritize which vaccine candidates to develop further.

However, it should be noted the companies are not making any claims that the vaccine has the ability to eliminate, cure, or contain SARS-CoV-2 at this time.

Copyright © 2020

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for